There were 1,684 press releases posted in the last 24 hours and 402,171 in the last 365 days.

Ziopharm Oncology Third Quarter 2018 Financial Results Conference Call Rescheduled to Nov. 12

BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that it has rescheduled its quarterly conference call to Monday, Nov. 12, at 8 a.m. ET to provide a corporate update and discuss financial results for the third quarter ended Sept. 30, 2018. The Company will file its Form 10-Q on Nov. 9.

The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The passcode for the conference call is 7763857. To access the slides and live webcast or the subsequent archived recording, visit the "Investors & Media" section of the Ziopharm website at The webcast will be recorded and available for replay on the Company's website for two weeks.

About Ziopharm Oncology, Inc.
Ziopharm Oncology is a biotechnology company focused on next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. Ziopharm is advancing the development of two platform technologies designed to deliver safe, effective, and scalable immunotherapies for the treatment of multiple cancer types: Controlled IL-12 platform for Ad-RTS-hIL-12 plus veledimex and Sleeping Beauty platform for genetically modifying T cells. Ad-RTS-hIL-12 plus veledimex has demonstrated controlled production of IL-12 in clinical trials leading to an infiltration of T cells to target solid tumors, including rGBM. Ad-RTS-hIL-12 plus veledimex is being evaluated as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer. The Company is also advancing immunotherapies using the Sleeping Beauty platform, a non-viral approach to genetically modifying T cells with DNA plasmids to express chimeric antigen receptors (CAR) and T-cell receptors (TCR) to target specific antigens in blood cancers and neoantigens in solid tumors. Sleeping Beauty is currently in a clinical trial to generate CD19-specific T cells and supports the Company's very short T-cell manufacturing process encompassed within the technology referred to as “point-of-care”. The platform is being advanced in collaboration with MD Anderson Cancer Center to generate CAR-expressing T cells and the National Cancer Institute to generate TCR-expressing T cells.

Company contacts:
David Connolly
Vice President, Corporate Communications and Investor Relations

Mike Moyer
Vice President, Portfolio Strategy

Ziopharm_RGB_hires (1).jpg